The listing application of Zhuhai Pusen Medical Technology Co., Ltd. (Pusen Medical) for the Shanghai Stock Exchange's STAR Market has progressed to the 'inquiry' stage.

Founded in 2014, the company is an innovative medical device enterprise specializing in the research, development, and manufacturing of single-use medical endoscopes.

It has established itself as a global technology pioneer, market developer, and industry leader in this field.

In March 2016, the company launched its single-use electronic ureterorenoscope at a major European urology conference, coinciding with a similar launch by global healthcare giant Boston Scientific.

It obtained CE marking for the product in April 2016, becoming the first Chinese and second global manufacturer to receive such certification for this device category.

In May 2017, it received 510(k) clearance from the U.S. FDA, again as the first Chinese and second global company for this product, and began commercial sales in the U.S. under its own PUSEN brand.

The product gained China NMPA Class III medical device registration in June 2020, initiating its commercialization within the domestic market.

The company has evolved from a product-focused firm into a platform-based one, expanding its portfolio across multiple endoscopic specialties.

Its product matrix now includes surgical lines featuring single-use ureteroscopes, cystoscopes, and choledochoscopes, and internal medicine lines such as single-use bronchoscopes.

These products, approved for sale in regions including China, the U.S., and the EU, address clinical needs in urology, hepatobiliary surgery, and pulmonology.

By innovating in materials and optoelectronic systems, the company has achieved mass production of its core UE3022 single-use ureteroscope, overcoming issues related to the complex reprocessing and infection risks of traditional reusable scopes.

Through over a decade of dedicated R&D focused on single-use ureteroscopy, the company has developed a series of products and accumulated core technologies.

These include ultra-slim outer diameter design, direct-instrument channel technology, direct in-scope suction (DISS™), and dual-channel technology, positioning it at the industry's forefront.

According to third-party market research, the company holds a leading position in the global single-use endoscope market based on projected 2025 shipment volumes.

In the single-use urological endoscope segment, it ranks first in the Chinese market with a 29.8% share and second in both the U.S. and EU markets with shares of 15.2% and 17.5%, respectively.

Within the flagship single-use ureteroscope category, it has achieved the top global market share of 20.4%, marking a successful transition from a domestic innovator to a global industry leader.

Financially, the company reported revenues of approximately 252 million yuan, 316 million yuan, and 538 million yuan for the years 2023, 2024, and 2025.

Net profits for the same periods were 69.36 million yuan, 57.95 million yuan, and 97.21 million yuan, respectively.